Can You Take NMN/NR With Pregabalin?

Why This Combination Raises Questions

Pregabalin (Lyrica) carries an FDA boxed warning regarding CNS depression and is classified as a Schedule V controlled substance due to abuse potential [1]. Patients taking pregabalin often ask whether supplements, particularly NAD+ precursors like nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR), could alter the drug's efficacy or amplify side effects.

The concern is reasonable. Pregabalin's most common adverse effects include somnolence (reported in 15.3% of fibromyalgia patients at 450 mg/day), dizziness (29.0%), and peripheral edema (5.4%) per the FDA-approved prescribing information [1]. Any supplement that might worsen these effects deserves scrutiny. NMN and NR have gained wide consumer adoption for their role as NAD+ precursors, with a 2023 systematic review identifying 34 registered human trials [2]. The overlap between populations taking pregabalin for neuropathic pain and those using NMN/NR for age-related NAD+ decline is growing.

Pharmacokinetic Analysis: Minimal Overlap

Pregabalin's pharmacokinetic profile makes it unusually resistant to drug-drug interactions. The drug undergoes negligible hepatic metabolism. Approximately 98% of an oral dose is recovered unchanged in urine [1]. It does not bind plasma proteins. It is neither a substrate nor an inhibitor of CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 [1].

NMN enters cells primarily through the SLC12A8 transporter identified in murine intestinal tissue [3]. Once intracellular, NMN is converted to NAD+ via nicotinamide mononucleotide adenylyltransferase (NMNAT) enzymes. NR uses equilibrative nucleoside transporters (ENTs) for cellular uptake and is phosphorylated to NMN by nicotinamide riboside kinases (NRK1/2) before entering the same NAD+ biosynthetic pathway [4].

Neither NMN nor NR has demonstrated inhibition of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), or organic anion/cation transporters (OATs/OCTs) in published data. Pregabalin's intestinal absorption relies on the L-type amino acid transporter system (LAT1, SLC7A5) rather than these efflux pumps [1]. The transport mechanisms are completely distinct.

A pharmacokinetic interaction would require one compound to alter the absorption, distribution, metabolism, or excretion of the other. Given that pregabalin avoids hepatic metabolism entirely and NMN/NR operates through the nicotinamide salvage pathway without engaging Phase I or Phase II drug-metabolizing enzymes, the probability of a clinically meaningful pharmacokinetic interaction is very low.

Pharmacodynamic Considerations

Pregabalin binds the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels, reducing calcium influx at nerve terminals and subsequently decreasing release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P [5]. This mechanism produces its analgesic, anxiolytic, and anticonvulsant effects, but also drives CNS depression.

NMN and NR function as NAD+ precursors. NAD+ participates in cellular energy metabolism (as a coenzyme for oxidoreductases), DNA repair (as a substrate for PARPs), epigenetic regulation (as a substrate for sirtuins), and calcium signaling (via CD38-mediated cyclic ADP-ribose synthesis) [6]. The CD38 connection to calcium signaling warrants brief examination.

CD38 consumes NAD+ to produce cyclic ADP-ribose (cADPR), which mobilizes intracellular calcium from ryanodine receptor stores [7]. Theoretically, raising NAD+ levels could increase cADPR production and alter intracellular calcium dynamics. However, this pathway operates on endoplasmic reticulum calcium stores, not on the voltage-gated calcium channels that pregabalin targets. Pregabalin acts at presynaptic terminals on α2δ-containing channels to reduce calcium-dependent neurotransmitter vesicle release [5]. These are mechanistically separate systems.

No published evidence supports additive CNS depression between NMN/NR and pregabalin. NMN/NR supplementation has not been associated with sedation, somnolence, or cognitive impairment in human trials. The MIB-626 phase I trial (NMN 1 to 000 mg daily, N=32) reported no CNS-related adverse events above placebo rates [8].

Renal Considerations Worth Monitoring

One area of legitimate clinical attention involves renal function. Pregabalin dosing is entirely dependent on creatinine clearance. The FDA label specifies dose reductions at CrCl 30-60 mL/min (50% reduction), CrCl 15-30 mL/min (75% reduction), and further reduction for patients on hemodialysis [1].

NAD+ metabolism generates nicotinamide (NAM) as a byproduct, which is methylated by nicotinamide N-methyltransferase (NNMT) to N-methyl-nicotinamide (MeNAM). MeNAM and its metabolites are renally cleared [9]. High-dose NMN/NR supplementation increases the renal load of these methylated metabolites. In patients with pre-existing renal impairment who are already on reduced pregabalin doses, the additional renal metabolite burden from NMN/NR is worth monitoring, though no case of clinically significant renal impairment from NMN/NR alone has been documented in humans.

A 2022 study in healthy adults receiving NR 1 to 000 mg twice daily for 6 weeks showed no change in estimated GFR or serum creatinine compared to placebo [10]. Still, for patients already at CrCl thresholds that affect pregabalin dosing, periodic metabolic panels remain reasonable clinical practice.

The Methyl Donor Question

High-dose NMN/NR supplementation places demands on the body's methyl donor pool. Converting excess nicotinamide to MeNAM requires S-adenosylmethionine (SAMe) as the methyl source [9]. Some clinicians have raised theoretical concerns about methyl depletion with chronic high-dose NAD+ precursor use.

Pregabalin's pharmacology does not intersect with methylation pathways. It is excreted unchanged. The methyl donor concern is relevant to NMN/NR supplementation in general rather than to this specific combination. Patients taking NMN/NR alongside multiple medications that undergo methylation-dependent metabolism (e.g., catechol-O-methyltransferase substrates) might face a different risk calculus, but pregabalin is not among them.

What the Clinical Literature Shows

A PubMed search for "nicotinamide mononucleotide pregabalin" or "nicotinamide riboside pregabalin" returns zero results as of May 2026. No case reports, no observational studies, no pharmacokinetic interaction trials exist for this combination.

The absence of literature cuts both ways. It likely reflects both the low theoretical risk (researchers study interactions with higher mechanistic plausibility) and the relatively recent widespread consumer adoption of NMN/NR. The Drugs.com and Lexicomp interaction databases do not flag NMN or NR as interacting with pregabalin. The FDA adverse event reporting system (FAERS) contains no signal for this combination [11].

"The absence of evidence for an interaction, combined with non-overlapping metabolic pathways, places this combination in the lowest tier of drug-supplement interaction concern," notes the American Society of Health-System Pharmacists' approach to evaluating theoretical interactions [12].

Neuropathy: A Shared Clinical Context

Many patients encounter this combination question because both compounds are used in neuropathic pain contexts. Pregabalin holds FDA approval for diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and spinal cord injury neuropathic pain [1]. NMN/NR supplementation has been explored for diabetic neuropathy based on preclinical data showing NAD+ depletion in dorsal root ganglia neurons exposed to high glucose conditions [13].

A 2020 preclinical study demonstrated that NMN (100 mg/kg intraperitoneally) attenuated mechanical allodynia in a chemotherapy-induced peripheral neuropathy mouse model, with the mechanism attributed to SIRT1-mediated mitochondrial protection in sensory neurons [14]. No human neuropathic pain trial with NMN/NR has been completed.

If both compounds act on neuropathic pain through different mechanisms (pregabalin via α2δ calcium channel modulation, NMN via NAD+-dependent neuronal metabolic support), the combination could theoretically be complementary rather than antagonistic. This remains speculative. No clinical trial has tested this hypothesis.

Practical Patient Counseling

For patients currently taking pregabalin who wish to add NMN or NR supplementation, the following clinical framework applies:

Pre-initiation: Confirm current pregabalin dose and renal function. Document baseline side effects (dizziness severity, edema status, somnolence level). This establishes whether any subsequent changes are attributable to the new supplement.

Dosing approach: Begin NMN/NR at lower doses (250-500 mg daily) rather than maximum studied doses (1,000-2 to 000 mg daily). This allows observation of tolerability over 2-4 weeks before escalation.

Monitoring parameters: Reassess at 2-4 weeks for any change in pregabalin-related side effects. Check basic metabolic panel if renal function was borderline at initiation. No specific drug level monitoring is available or indicated for either compound.

Red flags requiring medical contact: New or worsened peripheral edema, increased somnolence or dizziness beyond established baseline, unexplained changes in seizure control (for patients using pregabalin as anticonvulsant therapy), or signs of angioedema.

Contraindicated Combinations to Distinguish

While NMN/NR with pregabalin appears low-risk, patients should not extrapolate this safety profile to other combinations. Pregabalin carries genuine interaction risks with:

• Opioids: FDA warning added in 2019 regarding respiratory depression when combined with CNS depressants. A nested case-control study (N=191,973 opioid users) found pregabalin co-prescription associated with 1.68-fold increased odds of opioid-related death (95% CI: 1.19-2.36) [15].
• Alcohol: Additive CNS depression; pregabalin may potentiate ethanol motor and cognitive impairment [1].
• Thiazolidinediones (pioglitazone, rosiglitazone): Additive peripheral edema and potential weight gain [1].
• Benzodiazepines and sedative-hypnotics: Additive somnolence and dizziness; lorazepam co-administration increased the cognitive/motor impairment of pregabalin in pharmacodynamic studies [1].

These carry substantially higher evidence of harm than the NMN/NR combination.

The NAD+ Metabolism and Gabapentinoid Research Gap

The broader field of NAD+ precursor pharmacology remains underdeveloped relative to the supplement's popularity. A 2023 systematic review identified only 34 registered clinical trials for NMN and 47 for NR, most focused on biomarker endpoints rather than drug interaction profiles [2]. No systematic drug interaction screening program comparable to what the FDA requires for new drug applications has been applied to NMN or NR.

This gap means clinicians are reasoning from first principles (mechanism-based predictions) rather than empirical interaction data. For pregabalin specifically, the mechanistic prediction is reassuring: distinct absorption mechanisms, no shared metabolic enzymes, no overlapping receptor pharmacology, and no additive CNS depression signals.

The Endocrine Society has not issued guidance on NAD+ precursor supplementation with concomitant medications [16]. Until formal interaction studies are conducted, the combination falls into a monitoring-without-contraindication category.

Patients taking pregabalin 300 mg/day or higher who initiate NMN supplementation should have renal function confirmed within normal limits and report any change in pregabalin side-effect burden at their next follow-up visit.